Claims

1. Use of ~~A~~ a composition comprising each of lutein, zeaxanthin and meso-zeaxanthin; and a composition comprising at least one omega-3 fatty acid in the manufacture of a medicament~~;~~ for ~~use in~~ the treatment of Alzheimer's disease in a human subject having an MMSE score of 25 or less.

2. The ~~composition~~ use according to claim 1, wherein a single composition comprises each of lutein, zeaxanthin, meso-zeaxanthin and at least one omega-3 fatty acid.

3. The ~~composition~~ use according to claim 1 or 2, wherein the said at least one omega-3 fatty acid comprises docosahexaenoic acid.

4. The ~~composition~~ use according to any one of the preceding claims, wherein the said at least one omega-3 fatty acid is provided as a fish oil component in the composition.

5. The ~~composition~~ use according to any one of the preceding claims, wherein the said at least one omega-3 fatty acid comprises at least two fatty acids.

6. The ~~composition~~ use according to any one of the preceding claims, wherein the omega-3 fatty acid comprises docosahexaenoic acid and eicosapentaenoic acid.

7. The ~~composition~~ use according to any one of the preceding claims, wherein the said at least one omega-3 fatty acid is provided as the free acid, as a salt or as a trigylceride.

8. The ~~composition~~ use according to claim 7, wherein the salt comprises a monocation.

9. The ~~composition~~ use according to claim 8, wherein the salt comprises a metal monocation.

10. The ~~composition~~ use according to any one of the preceding claims, wherein the composition/s is/are formulated to be suitable for oral consumption and is/are administered orally.

11. The ~~composition~~ use according to any one of the preceding claims, wherein the composition/s is/are to be administered at least three times a week.

12. The ~~composition~~ use according to any one of the preceding claims, wherein the composition/s is/are to be administered daily.

13. The ~~composition~~ use according to any one of the preceding claims, wherein the composition/s is/are in unit dose form.

14. The ~~composition~~ use according to claim 13, wherein each unit dose of composition comprises 10mgs meso-zeaxanthin, 10mgs lutein, 2mgs zeaxanthin, and 1gm fish oil.

15. The ~~composition~~ use according to claim 13, wherein each unit dose of composition comprises 15mgs meso-zeaxanthin, 5mgs lutein, 1mg zeaxanthin, and 1gm fish oil.

16. The ~~composition~~ use according to claim 13, wherein each unit dose of the composition comprises between 20mgs and 2grams of docosahexaenoic acid.

17. The ~~composition~~ use according to any of one of the preceding claims, wherein the composition/s further comprise one or more of the following: acidity regulators; anticaking agents including sodium aluminosilicate, calcium or magnesium carbonate, calcium silicate, sodium or potassium ferricyanide; antioxidants including vitamin E, vitamin C, and polyphenols; colorings including artificial colorings FD&C Blue No. 1, Blue No. 2, Green No. 3, Red No. 40, Red No. 3, Yellow No. 5 and Yellow No. 6; and natural colorings caramel, annatto, cochineal, betanin, turmeric, saffron, paprika; color retention

agents; emulsifiers; flavours; flavour enhancers; preservatives; stabilizers; sweeteners and thickeners.

18. The ~~composition~~ use according to any one of the preceding claims, wherein the composition/s is/are in the form of a tablet or capsule.

19. The ~~composition~~ use according to any one of the preceding claims, wherein the ~~subject consumes the~~ composition/s is/are to be administered on a weekly or daily basis over a period of at least 6 months.

20. The ~~composition~~ use according to any of claims 1-18~~20~~, wherein the ~~subject consumes the~~ composition/s is/are to be administered on a weekly or daily basis over a period of at least 12 months.

21. The ~~composition~~ use according to any one of the preceding claims, wherein the composition substantially ~~consisting~~ consists of lutein, zeaxanthin, meso-zeaxanthin, at least one omega-3 poly-unsaturated fatty acid or corresponding salt or triglyceride, and a diluent, carrier or excipient.

22. The ~~composition~~ use according to claim 21, wherein the omega-3 poly-unsaturated fatty acid or corresponding salt or triglyceride is DHA or a salt or triglyceride of DHA.

23. The ~~composition~~ use according to any one of the preceding claims, wherein the composition ~~comprising~~ comprises each of lutein, zeaxanthin, meso-zeaxanthin and DHA and/or EPA, the composition being formulated in unit dose form for daily oral administration, for use in preventing or retarding the progression of cognitive impairment in a subject already exhibiting one or more symptoms of Alzheimer's disease prior to administration of the composition.